Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
PaperCitations, authors & open-access status
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 182 citations, 2019 year and bronze oa status.
182
Citations
2019
Year
bronze
OA Status